Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Depreciation and Depletion (2018 - 2025)

Serina Therapeutics' Depreciation and Depletion history spans 6 years, with the latest figure at $22000.0 for Q1 2025.

  • For Q1 2025, Depreciation and Depletion fell 29.03% year-over-year to $22000.0; the TTM value through Sep 2025 reached $185000.0, up 153.42%, while the annual FY2024 figure was $218000.0, 66.41% up from the prior year.
  • Depreciation and Depletion for Q1 2025 was $22000.0 at Serina Therapeutics, down from $163000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $163000.0 in Q4 2024 and bottomed at $13000.0 in Q1 2023.
  • The 3-year median for Depreciation and Depletion is $23000.0 (2024), against an average of $45166.7.
  • The largest annual shift saw Depreciation and Depletion surged 138.46% in 2024 before it fell 29.03% in 2025.
  • A 3-year view of Depreciation and Depletion shows it stood at $18000.0 in 2023, then soared by 805.56% to $163000.0 in 2024, then crashed by 86.5% to $22000.0 in 2025.
  • Per Business Quant, the three most recent readings for SER's Depreciation and Depletion are $22000.0 (Q1 2025), $163000.0 (Q4 2024), and $24000.0 (Q2 2024).